Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2011 Dec;26(12):1634-7.
doi: 10.3346/jkms.2011.26.12.1634. Epub 2011 Nov 29.

Fatal rhabdomyolysis in a patient with liver cirrhosis after switching from simvastatin to fluvastatin

Seung Don Baek  1 , Sun-Joo Jang, So-Eun Park, Tae Jin Ok, Jaechan Leem, Ho-Su Lee, So Jung Park, Tae Hee Kim
Affiliations
Case Reports

Fatal rhabdomyolysis in a patient with liver cirrhosis after switching from simvastatin to fluvastatin

Seung Don Baek et al. J Korean Med Sci. 2011 Dec.

Abstract

HMG-CoA reductase inhibitors (statins) are widely used to treat hypercholesterolemia. Among the adverse effects associated with these drugs are statin-associated myopathies, ranging from asymptomatic elevation of serum creatine kinase to fatal rhabdomyolysis. Fluvastatin-induced fatal rhabdomyolysis has not been previously reported. We describe here a patient with liver cirrhosis who experienced fluvastatin-induced fatal rhabdomyolysis. This patient had been treated with simvastatin (20 mg/day) for coronary artery disease and was switched to fluvastatin (20 mg/day) 10 days before admission. He was also taking aspirin, betaxolol, candesartan, lactulose, and entecavir. Rhabdomyolysis was complicated and continued to progress. He was treated with massive hydration, urine alkalization, intravenous furosemide, and continuous renal replacement therapy for acute renal failure, but eventually died due to rhabdomyolysis complicated by hepatic failure. In conclusion, fluvastatin should be used with caution in patients with liver cirrhosis, especially with other medications metabolized with CYP2C9.

Keywords: Fluvastatin; Liver Cirrhosis; Rhabdomyolysis; Simvastatin.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
A 99mTc-diphosphonate scintigram bone scan showed increased uptake over all extremities and muscles of the thorax and abdomen.
Fig. 2
Fig. 2
Changes in serum CK and PT concentrations during admission. CRRT, continous renal replacement therapy.
See this image and copyright information in PMC

References

    1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA. 2001;285:2486–2497. - PubMed
    1. Suh JW, Choi DJ, Chang HJ, Cho YS, Youn TJ, Chae IH, Kim KI, Kim CH, Kim HS, Oh BH, Park YB. HMG-CoA reductase inhibitor improves endothelial dysfunction in spontaneous hypertensive rats via down-regulation of caveolin-1 and activation of endothelial nitric oxide synthase. J Korean Med Sci. 2010;25:16–23. - PMC - PubMed
    1. Corsini A, Jacobson TA, Ballantyne CM. Fluvastatin: clinical and safety profile. Drugs. 2004;64:1305–1323. - PubMed
    1. Liberopoulos EN, Daskalopoulou SS, Mikhailidis DP, Wierzbicki AS, Elisaf MS. A review of the lipid-related effects of fluvastatin. Curr Med Res Opin. 2005;21:231–244. - PubMed
    1. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346:539–540. - PubMed

Publication types

MeSH terms